Company intelligence
Domainex
Driving Discovery - Delivering Leads
About Domainex
Domainex is a fully integrated drug discovery service company based near Cambridge, UK serving pharmaceutical, biotechnology, academic and patient foundations globally. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year for the past six years. Domainex’s highly experienced molecular, protein, structural and assay biologists plus medicinal, computational and analytical chemists can be leveraged through our CRO services. Domainex’s focus is on providing highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of drug targets. Domainex offers a range of services including: • Medicinal chemistry (including SBDD) • FragmentBuilder (Domainex’s proprietary fragment screening platform) • Computational Chemistry (including LeadBuilder Domainex’s proprietary virtual screening platform) • Assay Development and Screening (biochemical, biophysical and cell assays) • iPSC and immune cell biology • Protein Production • CDH (Domainex’s proprietary technology which enables the rapid identification of stable, soluble protein domains) • Analytical chemistry • X-ray crystallography services Whether your project is at an early stage of drug discovery or has already identified chemical matter, our processes have been shown to result in a 30% time-saving compared to industry standards and use less resource, allowing prudent management of your own budget.
Verified activity
Signals from Domainex
17 published signals
Presence & Recognition
Domainex is collaborating with One Nucleus for an upcoming webinar introducing Domainex's next-generation polymer nanodisc platform PureDisc.
Reported by Domainex
Presence & Recognition
Domainex is exhibiting at the EFMC European Federation for Medicinal Chemistry and Chemical Biology session at poster #216, outlining its membrane protein production platform enabled by PureDisc technology and benefits of biophysics screening and CryoEM structure improvements.
Reported by Ray Boffey
Presence & Recognition
Domainex participated in Day 2 of the European Federation for Medicinal Chemistry and Chemical Biology conference in Basel.
Reported by Ray Boffey
Presence & Recognition
Domainex is presenting a poster at Discovery on Target 2026 in Boston this September.
Reported by Chris Miller
Presence & Recognition
Domainex is attending the EFM Medical Chemistry 2026 conference to discuss PureDisc membrane protein solutions and D2B.
Reported by Chris Miller
Presence & Recognition
Domainex is now live at EFM Medical Chemistry 2026 at booth 2, featuring Rico Gerup Petersen, PhD on DEL screening of the transcription factor SOX2 and Trevor Askwith, PhD on PureDisc technology for membrane protein stabilisation.
Reported by Domainex
Presence & Recognition
Domainex is exhibiting at booth #2 at the EFMC European Federation for Medicinal Chemistry and Chemical Biology event to discuss integrated drug discovery projects.
Reported by Ray Boffey
Presence & Recognition
Domainex is attending the EFMC European Federation for Medicinal Chemistry and Chemical Biology event in 2026.
Reported by Ray Boffey
Presence & Recognition
Domainex is hosting a team meeting in Basel for the EFM Medical Chemistry conference in 2026
Reported by Chris Miller
Presence & Recognition
Domainex is hosting a webinar on trans-membrane and protein production and structural biology.
Reported by Ray Boffey
Presence & Recognition
Domainex will be present at the XXIX EFMC European Federation for Medicinal Chemistry and Chemical Biology symposium on medicinal chemistry in Basel, Switzerland.
Reported by Domainex
Presence & Recognition
Domainex will be joined by Rico Gerup Petersen from Vipergen ApS to discuss how their recent partnership for DEL screening can enable projects and discuss their molecular glue case study.
Reported by Domainex
Presence & Recognition
Domainex hosted a webinar featuring Jim Reid discussing challenges in membrane protein production and new technologies.
Reported by Ray Boffey
Presence & Recognition
Domainex announced that Ray Boffey will be joined by Trevor Askwith, the Head of Biology, at the EFMCMedicinalChemistry2026 event next week.
Reported by Ray Boffey
Presence & Recognition
Domainex hosted a webinar featuring Jim Reid discussing TRPML3 and membrane protein activity.
Reported by Domainex
Research & Knowledge
Domainex hosted Jim Reid's webinar detailing work on TRPML3 for membrane protein activity.
Reported by Chris Miller
Partnerships
Domainex announced a new partnership with Vipergen ApS to enhance lead discovery using DEL screening approaches.
Reported by Ray Boffey